U.S. FDA declines to approve Spero's urinary tract infection drug
27/06/2022 21:08
June 27 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc's SPRO.O oral antibiotic drug for the treatment of patients with complicated urinary tract infections, the company said on Monday. (Reporting by Amruta Khandekar; Editing by Shounak Dasgupta) ((Amruta.Khandekar@thomsonreuters.com))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)